

Clinical characteristics and current therapeutic approach of patients with synchronous primary endometrial and ovarian cancers

Androutsopoulos Georgios¹, Vitsas Charalampos¹, Thanatsis Nikolaos¹, Michail Georgios¹, Terzakis Emmanouel², Decavalas Georgios¹

¹Department of Obstetrics and Gynecology, University of Patras, Medical School, Rio, Patras, Greece

²Department of Gynecology, St. Savvas hospital, Athens, Greece

Correspondence

Androutsopoulos Georgios, Department of Obstetrics and Gynecology, University of Patras, Medical School, Rio, GR-26504, Greece. 21 Nikolaou Apostoli St, GR - 26332, Patras, Greece

E-mail: androutsopoulosgeorgios@hotmail.com

Abstract

Synchronous primary endometrial and ovarian cancers are relatively uncommon in general population. Although their pathogenesis still remains unclear, embryologic, hormonal, genetic or other phenomena may be responsible for the development of synchronous primary endometrial and ovarian cancers. The most common symptoms and signs in those patients are: abnormal uterine bleeding, abdominal/pelvic pain and abdominal/pelvic mass. For most patients with synchronous primary endometrial and ovarian cancers, systematic surgical staging is the baseline therapy and includes total abdominal hysterectomy with bilateral salpingo - oophorectomy, total omentectomy, appendectomy, pelvic and para - aortic lymphadenectomy, complete resection of all disease, biopsy of any suspected lesion and pelvic washings. Moreover, that therapeutic approach allows a more clear decision for stage related postoperative adjuvant therapy. The role

of postoperative adjuvant treatment in patients with synchronous primary endometrial and ovarian cancers, remains controversial. In most cases, postoperative adjuvant treatment should be individualized according to the risk of recurrence of each primary cancer. Particularly in patients with increased risk for recurrence or at advanced stage disease, postoperative adjuvant treatment customized to both cancers is required. Patients with synchronous primary endometrial and ovarian cancers have better overall survival than patients with single primary ovarian or endometrial cancer. Perhaps, favorable prognosis is associated with the detection of patients at early stage and low grade disease. Moreover, the clinical efficacy of the postoperative adjuvant treatment should be further investigated.

Key words: synchronous primary cancers; clinical characteristics; treatment

Synchronous primary cancers are relatively uncommon in general population¹⁻³. Among women with gynecologic malignancies, only 0.5 - 1.7%

have synchronous primary cancers of the female genital tract. The most common cancer combination in those patients, is synchronous primary en-

dometrial and ovarian cancers⁴⁻⁹.

Epidemiology

There are distinct clinical characteristics in patients with synchronous primary endometrial and ovarian cancers including young age, obesity, premenopausal status and nulliparity¹⁰. The median age at diagnosis of synchronous primary endometrial and ovarian cancers is 50 years^{4,9-15}. Usually, those patients are 10 - 20 years younger than patients with single endometrial or ovarian cancer^{5,12,13,15,16}.

Pathogenesis

Despite proposed theories, the pathogenesis of synchronous primary endometrial and ovarian cancers still remains unclear^{2,3,7,17}. An attractive explanation of the development of synchronous primary cancers in the female genital tract is the theory of the secondary Müllerian system^{6,7,17-19}. According to this theory, the common embryologic origin of the epithelia in the upper female genital tract, explains adequately their synchronous response to a carcinogenic stimulus (hormone, radiation, other)^{2,6,17,18}.

Possibly, common hormone receptors (estrogen receptors) in the upper female genital tract, are also responsible for the development of synchronous primary cancers^{6,7,19}. Moreover, patients with synchronous primary endometrial and ovarian cancers, may have a more fragile genome and prior genetic damage may predispose them to the development of synchronous primary cancers^{17,20-24}. Especially patients with Lynch syndrome, have an obvious predisposition to the development of multiple synchronous primary cancers (colon, endometrium, ovary, stomach, small bowel, ureter and renal pelvis)²⁵.

It is evident that embryologic, hormonal, genetic or other phenomena may be responsible for the development of synchronous primary endometrial and ovarian cancers^{6,7,17-20,22,25}.

Symptoms and signs

Patients with synchronous primary endometrial and ovarian cancers, have the following symptoms

and signs: abnormal uterine bleeding (46%), abdominal/pelvic pain (17%) and abdominal/pelvic mass (13%)^{1-3, 10, 12, 14, 15, 17, 26}.

Pathology

Synchronous primary endometrial and ovarian cancers may have similar or different histologic appearance^{7,11,16}. The distinction between synchronous primary and metastatic cancers is relatively easy, when they have different histologic types. However, the distinction is relatively difficult, when they have the same histologic type. In clinical practise, we use well described empirical criteria for the proper diagnosis of synchronous primary endometrial and ovarian cancers^{27,28}.

Treatment

Systematic surgical staging is the baseline therapy, for most patients with synchronous primary endometrial and ovarian cancers^{1,2,4,5,7,11-14,29-31}. That therapeutic approach allows a more clear decision for stage related postoperative adjuvant therapy^{1,2,30-33}.

In patients with synchronous primary endometrial and ovarian cancers, systematic surgical staging includes total abdominal hysterectomy with bilateral salpingo - oophorectomy, total omentectomy, appendectomy, pelvic and para - aortic lymphadenectomy, complete resection of all disease, biopsy of any suspected lesion and pelvic washings^{1,3,5,7,11-13,29-31,34,45}.

Appropriate surgical staging provides diagnostic, prognostic and therapeutic benefits for women with synchronous primary endometrial and ovarian cancers. It facilitates targeted therapy that maximize survival and minimize the morbidity of overtreatment (radiation injury, chemotherapy toxicity) and the effects of undertreatment (recurrent disease, increased mortality)^{1-3,32}.

The role of pelvic and para - aortic lymphadenectomy is crucial for patients with synchronous primary endometrial and ovarian cancers. It defines precisely the extent of disease and the prognosis of patients. Moreover, pelvic and para - aortic lym-

phadenectomy is very important to identify patients with stage III disease^{1-3,34,35}.

An independent risk factor for postoperative complications, is the extent of pelvic and para - aortic lymph node dissection (more than 14 lymph nodes)^{1-3,30,31,33,36-38}. Moreover, in elderly patients as well as in patients with relevant comorbidities (obesity, diabetes, coronary artery disease), morbidity should be carefully weighed against any survival advantage^{1-3,32,39,40}.

The role of postoperative adjuvant treatment in patients with synchronous primary endometrial and ovarian cancers, remains controversial^{11,14,41}. In most cases with synchronous primary endometrial and ovarian cancers, postoperative adjuvant treatment should be individualized according to the risk of recurrence of each primary cancer^{2,3,41,42}. Moreover, the postoperative adjuvant treatment of one primary cancer should not affect the postoperative adjuvant treatment of the other primary cancer^{2,3,43}.

Particularly in patients with increased risk for recurrence or at advanced stage disease, postoperative adjuvant treatment customized to both cancers is required^{1-4,7,12-14,16,26,29-31,41,43-45}. More specifically in those patients, postoperative adjuvant treatment includes radiotherapy and/or chemotherapy^{1-3,12,16,41}. Postoperative adjuvant radiotherapy includes: external pelvic radiotherapy and/or brachytherapy^{1-3,30,31,33}.

Vaginal brachytherapy is the adjuvant treatment of choice for intermediate risk endometrial cancer (EC) patients (stage IA grade 3 endometrioid type EC, stage IB grade 1 - 2 endometrioid type EC)⁴⁶⁻⁵². It is well tolerated, reduces the risk of local recurrences but has no impact on overall survival. Moreover, it is associated with less side effects and better quality of life. Especially for intermediate risk EC patients, vaginal brachytherapy is equivalent to external pelvic radiotherapy in achieving local control of disease^{46-51,53}.

External pelvic radiotherapy is used only in high risk EC patients (stage IB grade 3 endometrioid type EC, stage I non - endometrioid type EC)^{47-50,53}. It reduces the risk of local recurrences but has no impact

on overall survival^{32,46,48,51,54,55}. Moreover, it is associated with significant morbidity and reduction in quality of life^{46,54}.

Postoperative adjuvant chemotherapy is the appropriate treatment for patients with advanced stage disease^{1-3,42}. The most active chemotherapeutic agents for patients with synchronous primary endometrial and ovarian cancers, are taxanes, anthracyclines and platinum compounds^{12,14}.

The clinical efficacy of the postoperative adjuvant treatment should be further investigated⁴¹.

Prognosis

The most important prognostic factors for patients with synchronous primary endometrial and ovarian cancers include age, stage of ovarian cancer, grade of endometrial cancer and adjuvant treatment^{45,56-57}.

Patients with synchronous primary endometrial and ovarian cancers have 5 - year overall survival 85.9% and 10 - year overall survival 80.3%¹¹. It is obvious that patients with synchronous primary endometrial and ovarian cancers have better overall survival than patients with single primary ovarian or endometrial cancer^{1-3,10,41,43,45,58}. Moreover, patients with synchronous primary endometrial and ovarian cancers of endometrioid type have better overall survival than patients with non - endometrioid or mixed histologic types^{1-3,10,41,45}.

The better overall survival of those patients could be associated with the detection of patients at early stage and low grade disease^{1-4,7,11,21-23,26,29,58,59}. ■

Conflict of interest

All authors declare no conflict of interest.

References

1. Androutsopoulos G, Decavalas G. Synchronous primary endometrial and ovarian cancers. *J Community Med Health Educ* 2013;3:e120.
2. Androutsopoulos G, Decavalas G. Synchronous primary endometrial and ovarian cancers: pathogenesis, treatment and prognosis. *Int J Clin Ther Diagn* 2014;2:1-2.
3. Androutsopoulos G, Decavalas G. Synchronous pri-

- mary endometrial and ovarian cancers: a critical update. *Int J Gynecol Clin Pract* 2015 (in press).
4. Ayhan A, Yalçın OT, Tuncer ZS, Gürkan T, Küçükali T. Synchronous primary malignancies of the female genital tract. *Eur J Obstet Gynecol Reprod Biol* 1992;45:63-6.
 5. Tong SY, Lee YS, Park JS, Bae SN, Lee JM, Namkoong SE. Clinical analysis of synchronous primary neoplasms of the female reproductive tract. *Eur J Obstet Gynecol Reprod Biol* 2008;136:78-82.
 6. Deligdisch L, Szulman AE. Multiple and multifocal carcinomas in female genital organs and breast. *Gynecol Oncol* 1975;3:181-90.
 7. Eisner RF, Nieberg RK, Berek JS. Synchronous primary neoplasms of the female reproductive tract. *Gynecol Oncol* 1989;33:335-9.
 8. Matlock DL, Salem FA, Charles EH, Savage EW. Synchronous multiple primary neoplasms of the upper female genital tract. *Gynecol Oncol* 1982;13:271-7.
 9. Eser S, Gulhan I, Özdemir R, et al. Synchronous primary cancers of the female reproductive tract in Turkish women. *Asian Pac J Cancer Prev* 2011;12:857-9.
 10. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. *Gynecol Oncol* 2004;94:456-62.
 11. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas - a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. *Gynecol Oncol* 2001;83:355-62.
 12. Liu Y, Li J, Jin H, Lu Y, Lu X. Clinicopathological characteristics of patients with synchronous primary endometrial and ovarian cancers: A review of 43 cases. *Oncol Lett* 2013;5:267-70.
 13. Signorelli M, Fruscio R, Lissoni AA, Pirovano C, Perigo P, Mangioni C. Synchronous early - stage endometrial and ovarian cancer. *Int J Gynaecol Obstet* 2008;102:34-8.
 14. Chiang YC, Chen CA, Huang CY, Hsieh CY, Cheng WF. Synchronous primary cancers of the endometrium and ovary. *Int J Gynecol Cancer* 2008;18:159-64.
 15. Rodolakis A, Thomakos N, Akrivos N, et al. Clinicopathologic insight of simultaneously detected primary endometrial and ovarian carcinomas. *Arch Gynecol Obstet* 2012;285:817-21.
 16. Pearl ML, Johnston CM, Frank TS, Roberts JA. Synchronous dual primary ovarian and endometrial carcinomas. *Int J Gynaecol Obstet* 1993;43:305-12.
 17. Woodruff JD, Solomon D, Sullivant H. Multifocal disease in the upper genital canal. *Obstet Gynecol* 1985;65:695-8.
 18. Lauchlan SC. The secondary Mullerian system. *Obstet Gynecol Surv* 1972;27:133-46.
 19. Sica V, Nola E, Contieri E, et al. Estradiol and progesterone receptors in malignant gastrointestinal tumors. *Cancer Res* 1984;44:4670-4.
 20. Herrinton LJ, Voigt LF, Weiss NS, Beresford SA, Wingo PA. Risk factors for synchronous primary endometrial and ovarian cancers. *Ann Epidemiol* 2001;11:529-33.
 21. Terzakis E, Androutsopoulos G, Grigoriadis C, et al. Synchronous primary endometrial and fallopian tube cancers. *Eur J Gynaecol Oncol* 2010;31:467-8.
 22. Androutsopoulos G, Adonakis G, Tsamantas A, Liosis S, Antonopoulos A, Kourounis G. Synchronous primary cancers in a woman with scleroderma: a case report. *Eur J Gynaecol Oncol* 2008;29:548-50.
 23. Decavalas G, Adonakis G, Androutsopoulos G, et al. Synchronous primary endometrial and ovarian cancers: a case report. *Eur J Gynaecol Oncol* 2006;27:434-6.
 24. Grigoriadis C, Androutsopoulos G, Zygouris D, Arnogiannaki N, Terzakis E. Synchronous squamous cell carcinoma of the endometrium and endometrioid adenocarcinoma of the ovary. *Eur J Gynaecol Oncol* 2012;33:666-8.
 25. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. *Cancer* 1996;78:1149-67.
 26. Sheu BC, Lin HH, Chen CK, Chao KH, Shun CT, Huang SC. Synchronous primary carcinomas of the endometrium and ovary. *Int J Gynaecol Obstet* 1995;51:141-6.
 27. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. *Hum Pathol* 1985;16:28-34.

28. Scully R, Young R, Clement P. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Armed Forces Institute of Pathology/American Registry of Pathology WD, editor. Atlas of Tumor Pathology, 1998.
29. Androutsopoulos G, Adonakis G, Tsamandas A, Andonopoulos A, Decavalas G. Systemic sclerosis and multiple cancers of the female genital tract: prolonged survival following current treatment strategies. *Case Rep Rheumatol* 2011;2011:392068.
30. Androutsopoulos G, Decavalas G. Management of endometrial cancer. *Int J Transl Commun Med* 2013;1:101.
31. Androutsopoulos G. Current treatment options in patients with endometrial cancer. *J Community Med Health Educ* 2012;2:e113.
32. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician - gynecologists, number 65, August 2005: management of endometrial cancer. *Obstet Gynecol* 2005;106:413-25.
33. Androutsopoulos G, Decavalas G. Endometrial cancer: current treatment strategies. *World J Oncol Res* 2014;1:1-4.
34. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* 2014;124:1-5.
35. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009;105:103-4.
36. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early - stage endometrial carcinoma: randomized clinical trial. *J Natl Cancer Inst* 2008;100:1707-16.
37. Franchi M, Ghezzi F, Riva C, Miglierina M, Buttarelli M, Bolis P. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. *J Surg Oncol* 2001;78:232-7.
38. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. *Cochrane Database Syst Rev* 2010:CD007585.
39. Lachance JA, Darus CJ, Rice LW. Surgical management and postoperative treatment of endometrial carcinoma. *Rev Obstet Gynecol* 2008;1:97-105.
40. Lowery WJ, Gehrig PA, Ko E, Secord AA, Chino J, Havrilesky LJ. Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? *Gynecol Oncol* 2012;126:12-5.
41. Ma S, Zhang H, Sun Y, Wu L. Synchronous primary cancers of the endometrium and ovary: review of 43 cases. *Chinese - German Journal of Clinical Oncology* 2009;8:95-9.
42. Heitz F, Amant F, Fotopoulou C, et al. Synchronous ovarian and endometrial cancer - an international multicenter case - control study. *Int J Gynecol Cancer* 2014;24:54-60.
43. Castro IM, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Synchronous ovarian and endometrial malignancies. *Am J Clin Oncol* 2000;23:521-5.
44. Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. *Cancer* 1982;50:163-70.
45. Lim YK, Padma R, Foo L, et al. Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study. *J Gynecol Oncol* 2011;22:239-43.
46. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. *Cochrane Database Syst Rev* 2012:CD003916.
47. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high - intermediate risk (PORTEC - 2): an open - label, non - inferiority, randomised trial. *Lancet* 2010;375:816-23.
48. Burke WM, Orr J, Leitao M, et al. Endometrial cancer: a review and current management strategies: part II. *Gynecol Oncol* 2014;134:393-402.
49. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. *Ann Oncol* 2013;24 Suppl 6:vi33-8.
50. Chino JP, Jones E, Berchuck A, Secord AA, Havrilesky LJ. The influence of radiation modality and lymph node dissection on survival in early - stage endometrial cancer. *Int J Radiat Oncol Biol Phys* 2012;82:1872-9.

51. Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. *Curr Oncol Rep* 2011;13:472-8.
52. Sorbe BG, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium - risk endometrial carcinoma: a prospective, randomized study- - quality - of - life analysis. *Int J Gynecol Cancer* 2012;22:1281-8.
53. Creutzberg CL. GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? *Gynecol Oncol* 2004;92:740-3.
54. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage - 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. *Post Operative Radiation Therapy in Endometrial Carcinoma*. *Lancet* 2000;355:1404-11.
55. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2004;92:744-51.
56. Ayhan A, Guvenal T, Coskun F, Basaran M, Salman MC. Survival and prognostic factors in patients with synchronous ovarian and endometrial cancers and endometrial cancers metastatic to the ovaries. *Eur J Gynaecol Oncol* 2003;24:171-4.
57. Song T, Seong SJ, Bae DS, et al. Prognostic factors in women with synchronous endometrial and ovarian cancers. *Int J Gynecol Cancer* 2014;24:520-7.
58. Williams MG, Bandera EV, Demissie K, Rodríguez-Rodríguez L. Synchronous primary ovarian and endometrial cancers: a population - based assessment of survival. *Obstet Gynecol* 2009;113:783-9.
59. Van Altena AM, Geels YP, Bulten J, Kiemeneij LA, de Hullu JA, Massuger LF. Why do women with double primary carcinoma of the endometrium and ovary have a favorable prognosis? *Int J Gynecol Pathol* 2012;31:344-51.